Method of treatment tactics optimisation in case of hodgkin's lymphoma in children and teenagers
SUBSTANCE: invention relates to medicine, in particular to oncology, and can be used for optimisation of treatment tactics in case of Hodgkin's lymphoma in children and teenagers. Method is realised in the following way. Such unfavourable prognostic factors as: age over 10 years, IV stage of disease, conglomerate dimensions more than 5 cm and/or value of mediastinal-thoracic index greater than 0.33, number of affected zones more than 4, symptoms of intoxication and biological activity of process. After that three risk groups are determined by the sum of detected unfavourable factors. In the first group, if 0-2 factors are detected, 2 cycles of polychemotherapy in accordance with regimen VBVP are carried out, in the second group, if 3-4 risk factors are detected - 4 cycles in alternating regimen VBVP-ABVD-VBVP-ABVD, in the third group, if 5-6 factors are detected - 6 cycles in alternating regimen VBVP-ABVD-VBVP-ABVD-VBVP-ABVD. Two weeks after carrying out polychemotherapy in all groups irradiation of all earlier affected zones is performed.
EFFECT: method allows to reduce risk of post-cytostatic and radiation complications development due to reduction of treatment loading in patients.
1 tbl, 1 dwg, 2 ex
The invention relates to medicine, namely to methods of treatment of oncological diseases in children and adolescents.
Cytostatics with Hodgkin's lymphoma has been used 60 years ago in the form of monotherapy Mostaganem. The first sensational reports of high efficiency four-part schema of polychemotherapy of MORR (mustargen/embihin, oncovin/vincristine, procarbazine/natulan, prednisolone) appeared 20 years later (De Vita V. et al., 1967, 1970). However, with the increasing number of patients and prolonged periods of observation were identified and serious consequences of MORR (especially in children and adolescents): reduced fertility, largely observed in males; increased risk of second tumors and leukemias, etc. In the future, it was found that these complications are caused by the use of alkylating agents and natulan, but attempts to replace them led to worse outcomes. For 40 years it was tested a huge number of different schemes of chemotherapy, but only ABVD (adriblastin, bleomycin, vinblastine, dacarbazine), proposed G.Bonadonna et al. (1975), was able to compete with MORR efficiency, and its use was accompanied by a smaller number of remote consequences. Currently, ABVD is considered the "gold standard" in the treatment of Hodgkin lymphoma in adults despite the fact that h is on the large total doses of bleomycin may in some cases result in the development of pneumosclerosis, and use antracycline - cardiomyopathies. Currently, foreign literature extensively as about the long-term effects of treatment for Hodgkin's lymphoma, and the quality of life of treated patients. Observed a clear dependence of the frequency of the remote consequences of the number of alkylating drugs and their cumulative doses. So, G.Schellong et al. (1999) found that in 65% of patients with secondary tumors total dose of cyclophosphamide in the primary treatment of HL were 2-6 g/m2, procarbazine - 3-11 g/m2. As shown by the work A.T.Meadows et al. (1989), the risk of secondary hematological malignancies is increased in proportion to the number used alkylating agents over a period of 6 months. The study authors in all children with leukemia arising after treatment of primary Hodgkin's lymphoma, during this time interval was used, at least two agents with an alkylating action. Radiotherapy induces the emergence of second tumors solid structure, with two-thirds of these tumors (both malignant and benign nature) are localized in the zone or on the border of the radiation field.
In connection with this circumstance in oncidiinae great attention is paid to two directions of optimization of medical tactics in Hodgkin's disease: the use of schemes in Altamira the future mode, to a total dose of the most "dangerous" drugs did not exceed the threshold, and the exclusion of these drugs from used schemes. Perspective by reducing the total dose is the use of the principles of the so-called risk-adapted therapy, i.e. the dependence of the number of cycles of chemotherapy from risk (decrease therapeutic stress (radiation and cytostatic) at early stages of Hodgkin's lymphoma and intensification therapy for common forms of the disease).
The prototype of the claimed invention is a famous German-Austrian risk-adapted program DAL-HD. Since 1978, this research group has spent 6 consecutive treatment protocols for Hodgkin's lymphoma in children and adolescents (the total number of initial observations exceeds 2000). It is noted that when the high performance of these protocols could reduce the number of remote consequences (in particular, second tumors, and leukemias). It should be noted that in recent versions of the Protocol when stratification of risk groups are used only information about the stage of the disease and the General symptoms, and treatment schemes remain the anthracyclines and alkylating agents. DAL-HD has been adapted for our country (research Director G.Schellong) and put into practice sotrudnikami with Germany, oncopediatrie the fir branches. Our Department began to use the Protocol DAL-HD since 1987 (in cooperation with the former GDR), i.e. before other departments. There were obtained good results, which are, however, lower than reported by participants DAL-HD (especially in numbers event free survival). The risk of second neoplasms (particularly acute myeloid leukemia) was reduced from 10.4% to 0.9%. In our material, this fact was confirmed, however, the likelihood of myelogenous leukemia still remains (when increasing the observation period), which can be explained by the use of natulan and platinum. In the Protocol DAL-HD number used alkylating agents over a period of 6 months is 2-3, the cumulative dose of cyclophosphamide was 0-4,8 g/m2, procarbazine - 3-9 g/m2that, studies have shown A.T.Meadows et al.(1989), increases the risk of second neoplasms. Despite the fact that in our study, 60 patients of groups 1 and 2 (72,3%) cytotoxic loads were significantly reduced 5-year treatment outcomes (overall survival OS for the entire cohort treated equal for 93.4% with event free survival (EFS - 80,1%) can be considered satisfactory. However, there were a large number (12%) failures in the primary treatment, which, presumably, was the cause of the decline in event-free survival. Significant "RA the Bros" in figures in survival between the groups at risk, and, as is known, an indication of the imperfection of the principles of stratification of risk groups. Given the fact that almost half of the relapses occurred in non-irradiated lymph areas, the question as to the adequacy of the staging system, and the need to use in the stratification of risk groups larger number of prognostically significant factors.
In the present invention proposes a fundamentally new approach to the treatment of children and adolescents with Hodgkin's lymphoma.
The technical result of the invention is to optimize the treatment and reduction treatment loads in patients with early forms of the disease using risk-adapted Protocol Spbl-05.
When developing the original Protocol Spbl-05, we were guided by two factors: the use of inductive chemotherapy schemes that do not contain anthracyclines and alkylating cytostatics (or reduce their use to a minimum), and the desire to optimize the system randomization at risk by taking into account a larger number of prognostic factors. Was elected circuit VBVP, which, in our opinion, was sufficient to the task. "Weak point" of this scheme was the need to use relatively large total doses of bleomycin (90 mg/m
Certain changes took place in the system of stratification of risk groups. The latest forecast model (RF patent for the invention №2218861 "Method of optimizing therapeutic tactics with chlamydia in children. Kalugin B.A., Lebedev S. C. date of registration 20.12.03) enables patients as follows: 1 risk group includes 65,8% of patients, 2 - 17.8% and 3 - 16,4%, while when using the principles of stratification adopted in the DAL-HD, these figures are equal to 32.5%, 39.8% and 27.7 per cent respectively. In other words, the proposed system of stratification is twice the number of patients in group 1 (65,8% vs. 32,5%) and almost twice reduces the number of patients 3 groups (16.4% of vs. 27,7%). From this it follows that a greater number of patients significantly reduced cytotoxic load.
In the Protocol used stratified randomization. Stratification of risk groups is carried out depending on the values of the prognostic index (PI), emerging with regard to 6 signs (aged 10 years, the number of affected zones 4 or more, the size of the largest conglomerate of 5 cm or more and/or MIT more of 0.333, stage IV disease, the presence of common the symptoms and biological activity). It was slightly modified and the determination of the biological stage of the disease, because according to our data a significant impact on long-term results had only the values of the ESR, albumin level and anemia.
Patients randomizers into groups of low (group 1, P=0-2), intermediate (group 2, PI=3-4) and high (group 3, PI=5-6) risk, which determines the number of cycles inductive chemotherapy: patients of the 1st group risk (0-2 unfavorable prognostic signs) is 2 cycles of chemotherapy according to the scheme VBVP, 2 risk groups (3-4 symptom) to 4 cycles in alternating mode (VBVP-ABVD-VBVP-ABVD), 3 risk groups (5 or more symptoms) to 6 cycles in alternating mode (VBVP-ABVD-VBVP-ABVD-VBVP-ABVD). To consolidate remission after 2 weeks after drug therapy with normalization of blood counts is the exposure of all previously affected areas. SOD-specific lymphatic zone depends on the completeness of remission after drug therapy: when the achievement of complete remission in the lymph area or when reducing the size of the conglomerates in the PCT 75% or more of the original tumor SOD is typically 25 Grams, while the regression of a tumor less than 75% of 30-36 Gy; SOD to the lungs and liver - 12-15 Gr.
The objective of the invention was to develop a reliable determination of the scope of the treatment program, is to avoid "pereuchivaniya" patients while maintaining high survival rates.
For a better understanding of the essence of the invention claimed below is specific information about the use of this treatment program compared to the program DAL-HD.
Significant differences in survival rates depending on the applied Protocol is not marked: OS, DFS and EFS in the group "DAL-HD" was
94,9%, 90.9% 78,4%. in the group "Spbl-05" - 94,3%and 88.6% and 85.3%, respectively (log-rank test of 0.5-0.6).
Table 1 presents the performance of 3-year survival depending on the treatment Protocol and risk groups.
As can be seen in table 1, OS 1-th risk when using Protocol DAL-HD reached 100%, in the 2nd - 96,7%, 3rd - 87,0% at relapse-free survival (DFS) 88,0%, 95.6% of and 84,6% and EFS 84.4 per cent, 81,1% and 72.7%, respectively. Overall and disease-free survival in the 1st and the 2nd groups at risk when using Protocol Spbl-05 has reached 100%, in the 3rd - scores were equal to 83.1% and 60.3 percent, respectively. EFS in the 1st, 2nd and 3rd groups was of 92.9%, 100% and 53.8%, respectively.
Survival rates in the groups with low and intermediate risk indicate the validity of the proposed principles of stratification. Undoubtedly, the increase in the number of observations will make some adjustments in therapeutic tactics, which, in our opinion, will primarily affect 3 risk groups in which the number of patients will surely need in the early escalation of therapy (MEASOR, high the dose chemotherapy with hematopoietic stem cell transplantation).
Our approach to stratification of risk groups can reduce the medical burden (as cytostatic and radiation) on the child's body, which likely will reduce the risk of developing petticoating and radiation effects (the second tumor, cardiomyopathy, reduced fertility).
To enhance the specification of our proposals here are clinical examples:
1. Elena 3., 16, Hodgkin's lymphoma with lesions of the cervical-supraclavicular, intrathoracic and parietally lymph nodes (III AA senior). In accordance with the principles of stratification Protocol DAL-HD-90, the patient identified 2-I-risk group that requires 4 cycles of chemotherapy. However, using the prognostic index Protocol Spbl-05, the girl assigned to the 1st group risk, and therefore held 2 cycles of chemotherapy according to the scheme VBVP (without the use of alkylating drugs) and consolidating the irradiation of the affected areas in SOD-25 Gr. When observed within 2.5 years after completion of the treatment program, relapse, late complications are not detected.
3. Natalia R., age 4, Hodgkin's defeat of the nasopharynx, left cervical-supraclavicular, paraaortal lymph nodes, spleen (IIIS Century Art.). The treatment program was conducted according to the Protocol DAL-HD-90 and consisted of 6 cycles of chemotherapy (2 ORR and 4 CORR) and irradiation Shea is about-supraclavicular and paraaortal zones in SOD - 36-38 Gr (3-I-risk group). The amount of alkylating drugs amounted to 3, the total dose of cyclophosphamide - 4.8 g/m2, procarbazine - 9 g/m2. After 6 years after treatment diagnosed induced by cytostatics nelimpoblastny acute leukemia. When using our principles of stratification of the patient belonged to the 2nd group risk and would have received 4 courses of chemotherapy with single-agent alkylating action (dacarbazine).
A method of optimizing therapeutic tactics with Hodgkin's lymphoma in children and adolescents, including the detection of these adverse prognostic factors as: age more than 10 years, stage IV disease, the size of the conglomerate of more than 5 cm and/or value mediastinal-thoracic index more than 0.33, the number of affected areas more than 4 symptoms of intoxication and biological activity of the process, with subsequent determination of the three risk groups according to the amount of unfavorable factors, characterized in that in the first group when identifying 0-2 factors hold 2 cycles of chemotherapy according to the scheme VBVP, in the second group, with 3-4 risk factors - 4 cycle in alternating mode VBVP-ABVD-VBVP-ABVD in which cumulative dose of dacarbazine and doxorubicin is 750 and 100 mg/m2accordingly, in the third group with 5-6 risk factors 6 cycles in alternating mode VBVP-ABVD-VBVP-ABVD-VBVP-ABVD, the ri which cumulative dose of dacarbazine and doxorubicin is 1125 and 150 mg/m 2respectively; 2 weeks after completion of chemotherapy in all groups carry out the irradiation of all previously affected areas where SOD is 25 Grams, while achieving complete remission in the lymph area or when reducing the size of the conglomerates as a result of chemotherapy on 75% or more of the original tumor, and 30-36 Gy in regression of a tumor less than 75%.
SUBSTANCE: new pyrrolotriazine derivatives of general formula (I) are described, where R1 is possibly substituted piperidinyl or piperazinyl; R2 is possibly substituted phenyl; R3 is hydrogen; X is -NH-; Y is -CH2-; as well as their pharmaceutically acceptable salts or steroisomers, and pharmaceutical compositions containing said compounds.
EFFECT: given compounds are kinase inhibitors and can be used in medicine, for example as anticancer agents.
9 cl, 267 ex, 2 dwg
SUBSTANCE: invention relates to new derivatives of imidazo[1,2-c]pyrimidinyl acetic acid of formula (I) or to its salts: , where R1 is ,, in which n is an integer ranging from 0 to 6; Y is aryl, where the said aryl is optionally substituted at a substitutable position with one or more substitutes selected from a group which consists of halogen or C1-6alkyl, optionally substituted with mono-, di- or trihalogen; R2 is hydrogen; R3 is hydrogen or halogen; and R4 is hydrogen. The invention also relates to derivatives of imidazo[1,2-c]pyrimidinyl acetic acid of formula (I-i) or to its salts, to a drug, to use of compounds in paragraph 1, as well as to a drug in form of a standard single dosage.
EFFECT: obtaining new biologically active compounds, which are active towards CRTH2.
23 cl, 2 ex
SUBSTANCE: invention concerns medicine, oncology, and can be used for thermochemoradiation therapy of oesophagus cancer. That is ensured by local transoesophageal hyperthermia, gamma-ray teletherapy and chemotherapy as preoperative actions. Herewith gamma-ray therapy is carried out within 2 weeks in average fractionation mode at 3 Gy 5 times a week to total focal dose 30 Gy. Chemotherapy accompanies the whole course of gamma therapy by daily introduction of fluorouracil dosed 300 mg/m2 to the central vein in continuous infusion mode and daily intravenous introduction of cisplatin dosed 6 mg/m2 daily within 1 hour. Hyperthermia is applied on 4th, 8th and 12th days of gamma therapy immediately before irradiation session at temperature 42-44°C within 60 minutes.
EFFECT: method allows optimising treatment of the patients suffering from oesophagus cancer and improving clinical effectiveness owing to advanced local control.
SUBSTANCE: invention concerns medical products and covers applications of O- and S-glycosides 5-hydroxy-1,4-naphthoquinone (judlone) derivatives of formula 1 as an agent that stimulates human leukaemia cell apoptosis. Disclosed compounds selectively stimulate human leukemia cell apoptosis as comparrf with a prototype juglone without affecting normal cells of human immune system (neutrophils).
EFFECT: invention allows extending range of products selectively stimulating leukaemia cell apoptosis.
4 cl, 13 dwg, 5 tbl, 14 ex
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in chemotherapeutic treatment of locally advanced and general breast cancer. It is ensured by autoplasmochemotherapy. Every time before introduction of cytostatic agents incubated with autoplasma, Trental is introduced intravenously drop-by-drop in a dose 100 mg dissolved in physiologic saline 200 ml.
EFFECT: method improves clinical effectiveness and reduces toxicity of autoplasmochemotherapy due to potentiation of anticancer action of chemoprepatations and protection of blood and bone marrow cells.
SUBSTANCE: invention concerns medicine, namely oncology and can be used for neoadjuvant treatments of stomach cancer that is ensured by intraarterial introduction of taxotere 75 mg/m2 and cisplatin 75 mg/m2 with selective catheterisation of celiac trunk. Regional chemotherapy in number of 2 to 4 courses is performed.
EFFECT: application of the invention enables higher operability and clinical effectiveness ensured by downsising of tumour and loc-regional metastases.
SUBSTANCE: invention relates to medicine area, namely to oncology, and can be used for treatment of locally advanced non-small cell lung cancer. The therapy involves neoadjuvant chemotherapy, introduction of a radio sensitiser, surgical treatment and intraoperative radiation therapy. The preoperative period involves 2 courses of neoadjuvant chemotherapy with Taxol and carboplatin. Two hours before irradiation, gemcitabine is introduced in a dose 300 mg/m2, then radical operation with intraoperative radiation therapy in a single dose 15 Gy on regional lymphatic cancer spread area is performed.
EFFECT: invention allows improving clinical effectiveness of locally advanced non-small cell lung cancer owing to reduced post-radiation complications and higher survival rate of patients.
SUBSTANCE: invention refers to medicine and pharmacy, namely to agents for inhibition of development or progression of liver cancer in hepatitis C positive patients suffering from cirrhosis, wherein the agent contains three types of amino acids, namely isoleucine, leucine and valine, wherein mass ratio of isoleucine, leucine and valine makes 1:1.5-2.5:0.8-1.7.
EFFECT: invention provides effective inhibition of development or progression of liver cancer in hepatitis C positive patients suffering from cirrhosis.
18 cl, 1 ex, 1 dwg
SUBSTANCE: invention relates to new compounds of formula (I) and pharmaceutically acceptable salts of the said compound, which has c-met kinase inhibitory properties. In general formula (I) W is -N=, and X is hydrogen, Y is hydrogen or A2-R group; A2 is C1-C5alkylene; R is hydroxy; n equals 1, and Z is benzyloxy; or alternatively W is -CH=, and X is hydrogen, OR1; R1 is chosen from A1-Q1group; A1 is 1,2-ethylene or 1,3-propylene group; Q1 is hydroxyl; Y is a A2-R group; A2 is C1-C5alkylene; R is hydroxy; n equals 1, and Z is C1-C3alkoxy, substituted with pyridinyl, and pharmaceutically acceptable salts of the said compound.
EFFECT: can be used for treating cancer and cancer-related diseases.
8 cl, 36 ex
SUBSTANCE: invention relates to new phosphates of nitrophenylpyrite and nitrophenylaziridine alcohols of general formula , where: X represents -CONH- in any accessible position of the ring; R is a lower C1-6alkyl; Y represents -N-aziridinyl in any accessible position of the ring, -N(CH2CH2W)2 or -N(CH2CHMeW)2, where W is independently chosen from halogen or -OSO2Me; Z represents NO2 or -SO2Me in any accessible position of the ring; and its pharmaceutically acceptable salts. The invention also pertains to a method of producing phosphates of formula (I) and formulae , and (particular cases of formula (I)), a method of anticancer treatment and a method of destroying hypoxic cells using formula (I) compounds, as well as to a pharmaceutical composition based on formula (I) compounds.
EFFECT: obtaining new compounds which can be used as targeted cytotoxic agents.
14 cl, 5 tbl, 4 dwg, 39 ex
SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns an agent for inhibition of visceral fat uptake, for decrease in abdominal fat amount, and for prevention or reduction of visceral obesity that is considered as a principal factor of metabolic syndrome. There is presented agent or foodstuff, or drink containing 3-O-b-D-glucopyranosyl-4-methylergost-7-en-3-ole as a reacting component, extract in an organic solvent, extract in hot water, residual liquid of Liliaceae plant or its part which contains a compound.
EFFECT: agent possesses high clinical effectiveness with respect to visceral obesity.
6 cl, 2 ex, 2 tbl
SUBSTANCE: invention refers to medicine, namely to therapy, and concerns treatment of chronic arterial insufficiency. That is ensured by introduction of the preparation Antistax once a day in a dose 720 mg within 10 days, and then in a dose 320 mg within 20 days in addition to the conventional therapy involving antiaggregants, anticoagulants and vasodilators. Besides, Xymedone is introduced in a daily dose 1 g within 10 days in combination with machine pneumatic massage in mode "running wave" at duration of procedure 45 minutes and more and maximum pressure in chambers 100 mm Hg and less.
EFFECT: such complex of pharmacological aids introduced in developed doses and modes in combination with pneumatic massage provides effective treatment ensured by improved microcirculation and normalised lymphatic and venous blood flow.
SUBSTANCE: invention concerns medicine, particularly novel solid pharmaceutical composition of thelithromycin. Composition includes thelithromycin or one of its addition salts with pharmaceutically acceptable acid as active agent, and microcrystalline cellulose as inert filler with plastic properties.
EFFECT: reduced size of thelithromycin tablet at the same thelithromycin content, increased rupture strength of tablet.
12 cl, 1 dwg, 1 tbl, 1 ex
SUBSTANCE: invention relates to the new hem-difluoridated compound of the formula: where R1 represents a group, containing alkyl chain or amino group; R2 represents hydrogen atom, either free or protected functional group of alcohol; R3 represents a group CH2OH, CH2-OGP, where GP respresents protecting group such as alkyl, benzyl (Vp), trimethylsilyl (TMS), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), acetate (Ac); Y, Y', Y" represent independent groups OR, where R represents H, benzyl, Ac, TMS, TBDMS, TBDPS that are used for producing antitumor, antiviral, hypoglycemic and anti-flammatory medicine and compounds for immunology and cosmetology, or glyco peptide analogs of antifreeze molecules. The invention refers particularly also to the new hem-difluoridated compound of the general formula: and to the method of producing new hem-difluoridated compound of the formula: .
EFFECT: compounds possess increased effectiveness.
7 cl, 8 ex, 24 dwg
SUBSTANCE: invention refers to medicine, particularly to gynaecology, and concerns chronic adnexitis treatment that is ensured by course of general hydrogen sulphide baths of temperature 36-37°, concentration of 50-140 mg/l, within 8-10 minutes, 6-8 baths every second day and gynaecologic irrigations at temperature 38°, concentration to 140 mg/l, within 10-12 minutes for course 6-8 daily procedures. Panties-like applications of sulphide silt mud are performed at temperature 38-42°, within 10-15 minutes every second day. Additionally, there are applied vulval pads with ointment Ephthypeloid U containing as follows, wt %,: diclofenac - 0.5, furasolidone - 0.5, metronidazole - 0.1, Lydasa PE - 2 PE, tetracycline - 0.8, erythromycin - 0.5, nystatin - 0.5 g 500000 units - 1.0, calendula extract - 0.3, chestnut extract - 0.3, dalargin - 0.2, Solbrol M - 0.2, Solbrol P - 0.06, Solbrol BR - 0.3, Extrapone V - 0.16, Eftillin - 40.0 and sulphide silt mud of Suksunsky pond - 55.0 in amount 2-2.5 ml for 6-7 hours daily within course 6-8 procedures.
EFFECT: method provides intensified and accelerated complex analgetic, antiinflammatory, antimicrobic action of Ephthypeloid U components and as consequence, normalisation of microcirculation and acceleration repair processes.
SUBSTANCE: invention concerns chemical-pharmaceutical industry, and concerns medicinal compound on the basis of glycyrrhizic acid derivatives, allowing to increase bioavailability of the bonds considerably and can be used in medicine, virology, pharmacology, for example as an inhibitor of human immunodeficiency virus reproduction. The medicinal compound for inhibition of human immunodeficiency virus reproduction includes sodium carbonate and glycyrrhizic acid derivatives, the mass parity as part of di - and tri glycyrrhizic acid nicotinates and sodium carbonate lies in the range from 1:1 to 1:3.
EFFECT: increase of biologically active component - admixtures of di - and tri glycyrrhizic acid nicotinates bioavailability.
3 ex, 3 tbl
SUBSTANCE: way concerns medicine, namely to urology, and concerns treatment of the complicated clamidiosis of a urogenital tract of women and men. For this purpose azithromycin is entered slowly intravenously driply in a dose of 500 mg during 2-2.5 h. Introduction of azithromycin is performed on 1, 7 and 14 days of treatment. The way provides high therapeutic efficiency and prevention of relapses of disease at use of azithromycin in small doses, and also allows avoiding complications from a GI tract.
EFFECT: provision of high therapeutic efficiency and the prevention of relapses of disease at use of azithromycin in small doses, and also reception of possibility to avoid complications from a GI tract.
SUBSTANCE: in 1st, 9th, 17th and 24th days of therapy, 5-fluorouracil 750 mg and cisplatin 30 mg incubated with autoblood are introduced intravenously. In 7th, 15th and 23rd days, cisplatin 10 mg incubated with autoplasma, Novocaine 0.5% 20 ml, hydrocortisone 1.0 ml, analginum 50% 2.0 ml, vitamin B12 1.0 ml and gentamycin 1.6 g are introduced into presacral of small pelvis. From 10th to 14th days, 2 hours prior to radiotherapy session, a mixture containing Doxorubicin-Ebewe 5 mg, Viferon ointment 2.5 mg, Vinilin 2 ml, Synthomycin emulsion 2 ml and Dimexide 5% 4 ml is supplied to primary-site tumour through a perforated rubber tube. From 18th to 22th days, a mixture containing Mitomycin C 2.5 mg, Viferon ointment 2.5 mg, Vinilin 2 ml, Synthomycin emulsion 2 ml and Dimexide 5% 4 ml is supplied to primary-site tumour through a perforated rubber tube. After an 14-day recess, the therapeutical actions are repeated once again as specified.
EFFECT: involution of tumour, reduced radiation exposure and toxic by-effects of antitumour therapy.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions concerns medicine, in particular to oncology, and concerns cancer treatment with pegylated liposomal Doxorubicinum (PLD) in a combination with ecteinescidin 743 (ET-743). Versions of the method of treatment, versions of compositions, and also medical sets are offered for this purpose.
EFFECT: maintenance of effective suppression of a cancer tissue at the expense of combined influence of PLD and E-743 at depression of toxic effects.
41 cl, 1 dwg, 9 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns a pharmaceutical industry, in particular to compositions for treatment of adiposity and resistance to insulin at regulation of levels of glucose in blood. A way of treatment of adiposity and resistance to insulin at regulation of levels of a glucose in the blood, including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures, for resistance treatment to insulin at regulation of levels of a glucose and treatment of adiposity at the patient. Way of treatment of adiposity at the people, suffering diabetes, adiposity and resistance to insulin at regulation of levels of a glucose in blood and accepting a medicinal preparation for treatment of diabetes which includes introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures in a combination to an accepted medicinal preparation for regulation of levels of a glucose and treatment of the people, suffering diabetes. A way of treatment of adiposity and resistance to insulin at regulation of levels of a glucose in blood and the hyperglycaemia treatments, including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin and their admixtures, for treatment of adiposity, resistance to insulin and a hyperglycaemia. Way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and the lipide disturbances, including introduction of therapeutically effective quantity of the composition containing bond, representing an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin and lipide disturbances. Way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and a hypercholesterinemia, including introduction of therapeutically effective quantity of the composition containing bond, representing an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood, a hypercholesteremia. A way of treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and an atherosclerosis including introduction of therapeutically effective quantity of the composition containing bond, chosen from the group, including an anthocyanin, anthocyanidin or their admixtures, for treatment of adiposity, resistance to insulin at regulation of levels of a glucose in blood and an atherosclerosis. The above described ways of treatment of adiposity, resistance to insulin at regulation of levels of glucose in blood, lipide disturbances, a hypercholesterinemia, an atherosclerosis are effective.
EFFECT: working out of an effective way of treatment of adiposity and resistance to insulin.
16 cl, 9 dwg
SUBSTANCE: invention refers to medicine, namely to dentistry and can be used for local treatment of inflammatory parodentium diseases. That is ensured by removal of dental deposit with using an ultrasonic device "Ultrastom". Gingival pockets are irrigated with 0.05% miramistine. Then a gingival bandage containing mixed 2% calcium chloride, juice kalanchoe and great nettle, glucosamine hydrochloride, dimethyl sulphoxide and fused polyethylene PEO-400 and PEO-4000 with glycerine as a gel base is applied. Through the gingival bandage, parodentium tissues are exposed to low-frequency magnetic field of intensity 12-17 MTl of the device "Polus-1" within 20 minutes.
EFFECT: optimal relation of medicinal substances in the gingival bandage combined with magnetic field exposure ensures high therapeutic effect and reduced time of treatment of inflammatory parodentium diseases.